Method of resolution and antiviral activity of...

Details Method of resolution and antiviral activity of... Method of resolution and antiviral activity of...

2007-01-09

2007-01-09

Lewis, Patrick (Department: 1623)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S025400, C536S028100, C536S055300, C536S124000

Reexamination Certificate

active

10644293

ABSTRACT:
A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (−)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.

REFERENCES:
patent: 3116268 (1963-12-01), Farago
patent: 3116282 (1963-12-01), Hunter
patent: 3553192 (1971-01-01), Gauri
patent: 4000137 (1976-12-01), Dvonch et al.
patent: 4336381 (1982-06-01), Nagata et al.
patent: 4861759 (1989-08-01), Mitsuya et al.
patent: 4879277 (1989-11-01), Mitsuya et al.
patent: 4900828 (1990-02-01), Belica et al.
patent: 4916122 (1990-04-01), Chu et al.
patent: 4963533 (1990-10-01), de Clercq et al.
patent: 4968674 (1990-11-01), Taniyama et al.
patent: 5011774 (1991-04-01), Farina et al.
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5059690 (1991-10-01), Zahler et al.
patent: 5071983 (1991-12-01), Koszalka et al.
patent: 5089500 (1992-02-01), Daluge
patent: 5151426 (1992-09-01), Belleau et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5185437 (1993-02-01), Koszalka et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5215971 (1993-06-01), Datema et al.
patent: 5234913 (1993-08-01), Furman, Jr. et al.
patent: 5246924 (1993-09-01), Fox et al.
patent: 5248776 (1993-09-01), Chu et al.
patent: 5270315 (1993-12-01), Belleau et al.
patent: 5276151 (1994-01-01), Liotta
patent: 5409906 (1995-04-01), Datema et al.
patent: 5432165 (1995-07-01), Adair et al.
patent: 5444063 (1995-08-01), Schinazi
patent: 5446029 (1995-08-01), Eriksson et al.
patent: 5466806 (1995-11-01), Belleau et al.
patent: 5486520 (1996-01-01), Belleau et al.
patent: 5521161 (1996-05-01), Malley et al.
patent: 5532246 (1996-07-01), Belleau et al.
patent: 5538975 (1996-07-01), Dionne
patent: 5539116 (1996-07-01), Liotta et al.
patent: 5587480 (1996-12-01), Belleau et al.
patent: 5618820 (1997-04-01), Dionne
patent: 5663320 (1997-09-01), Mansour et al.
patent: 5684164 (1997-11-01), Belleau
patent: 5693787 (1997-12-01), Mansour
patent: 5696254 (1997-12-01), Mansour
patent: 5700937 (1997-12-01), Liotta et al.
patent: 5728575 (1998-03-01), Liotta et al.
patent: 5744596 (1998-04-01), Mansour
patent: 5756706 (1998-05-01), Mansour
patent: 5814639 (1998-09-01), Liotta et al.
patent: 5827727 (1998-10-01), Liotta et al.
patent: 5892025 (1999-04-01), Liotta
patent: 5914331 (1999-06-01), Liotta et al.
patent: 5914400 (1999-06-01), Liotta et al.
patent: 6069252 (2000-05-01), Liotta et al.
patent: 6153751 (2000-11-01), Liotta et al.
patent: 6346627 (2002-02-01), Liotta et al.
patent: 6642245 (2003-11-01), Liotta et al.
patent: 6703396 (2004-03-01), Liotta et al.
patent: 630913 (1992-11-01), None
patent: 665187 (1995-12-01), None
patent: 0 206 497 (1986-12-01), None
patent: 0 217 580 (1987-04-01), None
patent: 0 285 884 (1988-10-01), None
patent: 0 337 713 (1989-10-01), None
patent: 0 350 811 (1990-01-01), None
patent: 0 352 248 (1990-01-01), None
patent: 0 357 009 (1990-03-01), None
patent: 0 361 831 (1990-04-01), None
patent: 0 375 329 (1990-06-01), None
patent: 0 382 526 (1990-08-01), None
patent: 0 409 227 (1991-01-01), None
patent: 0 421 636 (1991-04-01), None
patent: 0 433 898 (1991-06-01), None
patent: 0 494 119 (1992-07-01), None
patent: 0 515 144 (1992-11-01), None
patent: 0 515 156 (1992-11-01), None
patent: 0 515 157 (1992-11-01), None
patent: 0 526 253 (1993-02-01), None
patent: 07109221 (1995-11-01), None
patent: 8901258 (1990-12-01), None
patent: 0238017 (1994-06-01), None
patent: WO 88/07532 (1988-10-01), None
patent: WO 88/08001 (1988-10-01), None
patent: WO 90/12023 (1990-10-01), None
patent: WO 91/09124 (1991-06-01), None
patent: WO 91/11186 (1991-08-01), None
patent: WO 91/17159 (1991-11-01), None
patent: WO 92/06102 (1992-04-01), None
patent: WO 92/08727 (1992-05-01), None
patent: WO 92/10496 (1992-06-01), None
patent: WO 92/10497 (1992-06-01), None
patent: WO 92/14729 (1992-09-01), None
patent: WO 92/14743 (1992-09-01), None
patent: WO 92/15308 (1992-09-01), None
patent: WO 92/15309 (1992-09-01), None
patent: WO 92/18517 (1992-10-01), None
patent: WO 92/21676 (1992-12-01), None
patent: WO 93/03027 (1993-02-01), None
patent: WO 93/23021 (1993-11-01), None
patent: WO 94/04154 (1994-03-01), None
patent: WO 94/09793 (1994-05-01), None
patent: WO 94/14456 (1994-07-01), None
patent: WO 94/14802 (1994-07-01), None
patent: WO 94/14831 (1994-07-01), None
patent: WO 94/27590 (1994-12-01), None
patent: WO 94/27616 (1994-12-01), None
patent: WO 95/07086 (1995-03-01), None
patent: WO 95/07287 (1995-03-01), None
patent: WO 95/18137 (1995-07-01), None
patent: WO 95/20595 (1995-08-01), None
patent: WO 95/21183 (1995-08-01), None
patent: WO 96/07413 (1996-03-01), None
patent: WO 96/40164 (1996-12-01), None
patent: WO 00/22157 (2000-04-01), None
Hoong et al. J. Org. Chem. (1992), vol. 57, pp. 5563-5565.
Secrist et al. J. Med. Chem. (1987), vol. 30, pp. 746-749.
Abobo, et al, “Pharmacokinetics of 2′, 3′-Dideoxy-5-fluoro-3′-thiacytidine in Rats,”J. of Pharmaceutical Sciences, 83(1):96-99 (1994).
Agrant and Biedermann, “Intellectual Property and Chirality: Patentability of Enantiomers of Racemic Drugs in a Racemic Switch Scenario,” Institute for Advanced Studies at The Hebrew University of Jerusalem,8th Chirality Conference, Edinburgh, UK (Jul. 2, 1996).
Beach, J.W., et al., “Synthesis of Enantiomerically Pure (2′R,5′S)-(1)-1-[2-hydroxymethyl)-oxatiolan-5-yl] Cytosine as a Potent Antiviral Agent Against Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV),”J. Org. Chem., 57:2217-2219 (1992).
Belleau, B., et al., “Design and Activity of a Novel Class of Nucleoside Analogs Effective Against HIV-I,”International Conference on AIDS, Montreal, Quebec, Canada, Jun. 4-9, 1989.
Borthwick, A.D., et al., “Synthesis and Enzymatic Resolution of Carbocyclic 2′-Ara-Fluoro Guanosine: A Potent New Anti-Herpetic Agent,”J. Chem. Soc. Cornmun., 10:656-658 (1988).
Chang, C.-N., et al, “Deoxycytidine Deaminase-resistant Steroisomer Is the Active Form of (±)-2′,3′-Dideoxy-3′-thiacytidine in the Inhibition of Hepatitis B Virus Replication,”The Journal of Biological Chemistry, 267(20):13938-13942 (1992).
Chang, C-N., et al., Biochemical Pharmacology of (+) and (−)-2′,3′-Dideoxy-3′-Thiacytidine as Anti-Hepatitis B Virus Agents,J. Biol. Chem., 267(31):22414-22420 (1992).
Choi, et al, “In Sim Complexation Directs the Stereochemistry of N-Glycosylation in the Synthesis of Oxathiolanyl and Dioxolanyl Nucleoside Analogues,”J. Am. Chem. Soc., 113:9377-9379 (1991).
Choi, et al., “Synthesis, Anti-Human Immunodeficiency Virus, and Anti-Hepatitis B Virus Activity of Pyrimidine Oxathiolane Nucleosides,”Bioorgan. and Med. Chem. Lett., 3(4):693-696 (1993).
Chu, et al., “Structure-Activity Relationships of Pyrimidine Nucleosides as Antiviral Agents for Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells,”J. Med. Chem., 32(3):612-617 (Mar. 1989).
Coates, et al., “The Separated Enantiomers of 2′-Deoxy-3′-thiacytidine(BCH-189) Both Inhibit Human Immunodeficiency Virus ReplicationIn Vitro,” Antimicrob. Agents Chemother., 36(1):202-205 (1992).
Condreay, et al., “Evaluation of the Potent Anti-Hepatitis B Virus Agent (−)cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolan-5-yl]Cytosine in a Novel In Vivo Model,”Antimicrobial Agents and Chemotherapy, 38(3):616-619 (Mar. 1994).
Connolly, et al., “Minireview: Antiretroviral Therapy: Reverse Transcriptase Inhibition,”Antimicrobial Agents and Chemotherapy, 36(2):245-254 (1992).
Doong, Shin-Lian., et al., “Inhibition of the Replication of Hepatitis B Virusin vitroby 2′,3′

Affiliated with

Also associated with

Rating

Method of resolution and antiviral activity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of resolution and antiviral activity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of resolution and antiviral activity of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3770570